Drug Profile
WP 1303 - Worg Pharmaceuticals
Alternative Names: Antigen processing-independent epitopes - Apitope Technology; API 1,4,6,7; ATX MS 1467; ATX-MS-01; M-2736; MSC2358825A; WP-1303 - Worg PharmaceuticalsLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Apitope Technology
- Developer Apitope Technology; Worg Pharmaceuticals (Hangzhou)
- Class Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple sclerosis
- Phase I Uveitis
Most Recent Events
- 19 Aug 2022 Phase-I development in Multiple-sclerosis is ongoing in Russia and United Kingdom (Intradermal, Injection) (Worg Pharmaceuticals pipeline, August 2022)
- 19 Aug 2022 Phase-I development in Multiple-sclerosis is ongoing in Russia and United Kingdom (SC, Injection) (Worg Pharmaceuticals pipeline, August 2022)
- 19 Aug 2022 Phase-II development in Multiple-sclerosis is ongoing in Latvia and Germany (Intradermal) (Worg Pharmaceuticals pipeline, August 2022)